Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
110 hedge funds and large institutions have $508M invested in Keryx Biopharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 42 increasing their positions, 37 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
84% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $17M
30% more capital invested
Capital invested by funds: $390M → $508M (+$118M)
14% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 37
8% more funds holding
Funds holding: 102 → 110 (+8)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.1M |
| 3 |
Renaissance Technologies
New York
|
+$8.82M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.3M |
| 5 |
HCM
Harvey Capital Management
Palm Beach,
Florida
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.1M |
| 2 |
DM
Deerfield Management
New York
|
-$17.9M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$10.5M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$8.84M |
| 5 |
Millennium Management
New York
|
-$6.55M |
KERX Hedge Fund Activity: Q3 2013 in Review
110 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2013, worth a combined $508M — up 30% from $390M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KERX positions and 7 closed out — a net gain of 9 holders — while 42 added to existing stakes and 37 trimmed.
The largest buyer was Ameriprise, adding an estimated $11.7M. The largest seller was RA Capital Management, cutting an estimated $29.1M.
- 110 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2013, up from 102 in Q2 2013.
- Funds reported $508M of Keryx Biopharmaceuticals Inc stock for Q3 2013, up 30% quarter-over-quarter.
- 16 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2013 and 7 closed out, a net change of +9 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2013 was Ameriprise, an estimated $11.7M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2013 was RA Capital Management, an estimated $29.1M sold.
Based on aggregated 13F filings for Q3 2013.